FLT1 and glioblastoma: Interestingly, EZH2 inhibitors (MC4040 and MC4041) not only reverse the pro-inflammatory phenotype of GBM U-87 and GL-1 cells by downregulating the levels of H3K27me3, but also inhibit epithelial-mesenchymal transition and migration of primary GBM tumor cells by reducing the level of VEGF and VEGFR1, resulting in inhibiting GBM cell proliferation and invasion of GBM (96).